Evidence for interaction of the NLRP3 inflammasome and Bruton’s tyrosine kinase in tumor-associated macrophages: implications for myeloid cell production of interleukin-1beta

References

• Yang L, Zhang Y. Tumor-associated macrophages: from basic research to clinical application. J Hematol Oncol. 2017;10:1. doi:10.1186/s13045-017-0430-2.
   PubMed Web of Science ®Google Scholar
• Benner B, Scarberry L, Suarez-Kelly LP, Duggan MC, Campbell AR, Smith E, Lapurga G, Jiang K, Butchar JP, Tridandapani S, et al. Generation of monocyte-derived tumor-associated macrophages using tumor-conditioned media provides a novel method to study tumor-associated macrophages in vitro. J ImmunoTher Cancer. 2019;7:140. doi:10.1186/s40425-019-0622-0.
   PubMed Web of Science ®Google Scholar
• Lee J, Wan J, Lee L, Peng C, Xie H, Lee C. Study of the NLRP3 inflammasome component genes and downstream cytokines in patients with type 2 diabetes mellitus with carotid atherosclerosis. Lipids Health Dis. 2017;16:217. doi:10.1186/s12944-017-0595-2.
   PubMed Web of Science ®Google Scholar
• Ghonime MG, Shamaa OR, Das S, Eldomany RA, Fernandes-Alnemri T, Alnemri ES, Gavrilin MA, Wewers MD. Inflammasome priming by lipopolysaccharide is dependent upon ERK signaling and proteasome function. J Immunol. 2014;192:3881–13. doi:10.4049/jimmunol.1301974.
   PubMed Web of Science ®Google Scholar
• Mariathasan S, Weiss DS, Newton K, McBride J, O’Rourke K, Roose-Girma M, Lee WP, Weinrauch Y, Monack DM, Dixit VM. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature. 2006;440:228–232. doi:10.1038/nature04515.
   PubMed Web of Science ®Google Scholar
• Perregaux D, Gabel CA. Interleukin-1 beta maturation and release in response to ATP and nigericin. Evidence that potassium depletion mediated by these agents is a necessary and common feature of their activity. J Biol Chem. 1994;269:15195–15203.
   PubMed Web of Science ®Google Scholar
• Heid ME, Keyel PA, Kamga C, Shiva S, Watkins SC, Salter RD. Mitochondrial reactive oxygen species induces NLRP3-dependent lysosomal damage and inflammasome activation. J Immunol. 2013;191:5230–5238. doi:10.4049/jimmunol.1301490.
   PubMed Web of Science ®Google Scholar
• Sha W, Mitoma H, Hanabuchi S, Bao M, Weng L, Sugimoto N, Liu Y, Zhang Z, Zhong J, Sun B, et al. Human NLRP3 inflammasome senses multiple types of bacterial RNAs. Proc Natl Acad Sci U S A. 2014;111:16059–16064. doi:10.1073/pnas.1412487111.
   PubMed Web of Science ®Google Scholar
• Broz P, Monack DM. Molecular mechanisms of inflammasome activation during microbial infections. Immunol Rev. 2011;243:174–190. doi:10.1111/j.1600-065X.2011.01041.x.
   PubMed Web of Science ®Google Scholar
• Dubois H, Wullaert A, Lamkanfi M. General strategies in inflammasome biology. In: Inflammasome signaling and bacterial infections. Cham: Springer; 2016. p. 1–22. doi: 10.1007/978-3-319-41171-2_1
   Google Scholar
• Ito M, Shichita T, Okada M, Komine R, Noguchi Y, Yoshimura A, Morita R. Bruton’s tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury. Nat Commun. 2015;6:7360. doi:10.1038/ncomms8360.
   PubMed Web of Science ®Google Scholar
• Fink SL, Cookson BT. Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells. Infect Immun. 2005;73:1907–1916. doi:10.1128/IAI.73.4.1907-1916.2005.
   PubMed Web of Science ®Google Scholar
• Elkabets M, Ribeiro VSG, Dinarello CA, Ostrand‐Rosenberg S, Di Santo JP, Apte RN, Vosshenrich CA.IL-1β regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function. Eur J Immunol. 2010;40:3347–3357. doi:10.1002/eji.201041037.
   PubMed Web of Science ®Google Scholar
• Rip J, de Bruijn MJW, Appelman MK, Pal Singh S, Hendriks RW, Corneth OB.Toll-like receptor signaling drives btk-mediated autoimmune disease. Front Immunol. 2019;10:95. doi:10.3389/fimmu.2019.00095.
   PubMed Web of Science ®Google Scholar
• Marron TU. The role of BTK in TLR signaling. J Allergy Clin Immunol. 2009;123:S92–S92. doi:10.1016/j.jaci.2008.12.329.
   Web of Science ®Google Scholar
• Levy O. Bruton tyrosine kinase (Btk): key for signaling via toll-like receptor 8. Blood. 2007;109:2273–2274. doi:10.1182/blood-2006-12-064642.
   Web of Science ®Google Scholar
• Burger JA, Wiestner A. Targeting B cell receptor signalling in cancer: preclinical and clinical advances. Nat Rev Cancer. 2018;18:148–167. doi:10.1038/nrc.2017.121.
   PubMed Web of Science ®Google Scholar
• Seda V, Mraz M. B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells. Eur J Haematol. 2015;94:193–205. doi:10.1111/ejh.12427.
   PubMed Web of Science ®Google Scholar
• Xia B, Qu F, Yuan T, Zhang Y. Targeting Bruton’s tyrosine kinase signaling as an emerging therapeutic agent of B-cell malignancies. Oncol Lett. 2015;10:3339. doi:10.3892/OL.2015.3802.
   PubMed Web of Science ®Google Scholar
• Woyach JA, Johnson AJ, Byrd JC. The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood. 2012;120:1175–1184. doi:10.1182/blood-2012-02-362624.
   PubMed Web of Science ®Google Scholar
• Stiff A, Trikha P, Wesolowski R, et al. Myeloid-derived suppressor cells express bruton’s tyrosine kinase and can be depleted in tumor-bearing hosts by ibrutinib treatment. Cancer Res. 2016;76:2125–2136. doi:10.1158/0008-5472.CAN-15-1490.
   PubMed Web of Science ®Google Scholar
• Fiedler K, Sindrilaru A, Terszowski G, Kokai E, Feyerabend TB, Bullinger L, Rodewald H-R, Brunner C. Neutrophil development and function critically depend on Bruton tyrosine kinase in a mouse model of X-linked agammaglobulinemia. Blood. 2011;117:1329–1339. doi:10.1182/blood-2010-04-281170.
   PubMed Web of Science ®Google Scholar
• Mueller H, Stadtmann A, Van Aken H, Hirsch E, Wang D, Ley K, Zarbock A. Tyrosine kinase Btk regulates E-selectin-mediated integrin activation and neutrophil recruitment by controlling phospholipase C (PLC) 2 and PI3K pathways. Blood. 2010;115:3118–3127. doi:10.1182/blood-2009-11-254185.
   PubMed Web of Science ®Google Scholar
• Honda F, Kano H, Kanegane H, Nonoyama S, Kim E-S, Lee S-K, Takagi M, Mizutani S, Morio T. The kinase Btk negatively regulates the production of reactive oxygen species and stimulation-induced apoptosis in human neutrophils. Nat Immunol. 2012;13:369–378. doi:10.1038/ni.2234.
   PubMed Web of Science ®Google Scholar
• Chang BY, Huang MM, Francesco M, Chen J, Sokolove J, Magadala P, Robinson WH, Buggy JJ. The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res Ther. 2011;13:R115. doi:10.1186/ar3400.
   PubMed Web of Science ®Google Scholar
• Dubovsky JA, Beckwith KA, Natarajan G, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013;122:2539–2549. doi:10.1182/blood-2013-06-507947.
   PubMed Web of Science ®Google Scholar
• Janda E, Palmieri C, Pisano A, Pontoriero M, Iaccino E, Falcone C, Fiume G, Gaspari M, Nevolo M, Di Salle E, et al. Btk regulation in human and mouse B cells via protein kinase C phosphorylation of IBtkγ. Blood. 2011;117:6520–6531. doi:10.1182/blood-2010-09-308080.
   PubMed Web of Science ®Google Scholar
• Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12:298–306. doi:10.1038/nrc3245.
   PubMed Web of Science ®Google Scholar
• Duggan MC, Regan-Fendt K, Olaverria GN, Howard JH, Stiff AR, Sabella J, Latchana N, Markowitz J, Gru A, Tridandapani S, et al. Neuroblastoma RAS viral oncogene homolog mRNA is differentially spliced to give five distinct isoforms: implications for melanoma therapy. Melanoma Res. 2019:1. doi:10.1097/CMR.0000000000000623.
   PubMedGoogle Scholar
• Stiff A, Trikha P, Mundy-Bosse B, McMichael E, Mace TA, Benner B, Kendra K, Campbell A, Gautam S, Abood D, et al. Nitric oxide production by myeloid-derived suppressor cells plays a role in impairing Fc receptor–mediated natural killer cell function. Clin Cancer Res. 2018;24:1891–1904. doi:10.1158/1078-0432.CCR-17-0691.
   PubMed Web of Science ®Google Scholar
• Mace TA, Shakya R, Pitarresi JR, Swanson B, McQuinn CW, Loftus S, Nordquist E, Cruz-Monserrate Z, Yu L, Young G, et al. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. Gut. 2018;67:320–332. doi:10.1136/gutjnl-2016-311585.
   PubMed Web of Science ®Google Scholar
• Chalons P, Amor S, Courtaut F, Cantos-Villar E, Richard T, Auger C, Chabert P, Schni-Kerth V, Aires V, Delmas D. Study of potential anti-inflammatory effects of red wine extract and resveratrol through a modulation of interleukin-1-beta in macrophages. Nutrients. 2018:10. doi:10.3390/nu10121856.
   PubMed Web of Science ®Google Scholar
• Edlund H, Lee SK, Andrew MA, Slatter JG, Aksenov S, Al-Huniti N. Population pharmacokinetics of the BTK inhibitor acalabrutinib and its active metabolite in healthy volunteers and patients with B-cell malignancies. Clin Pharmacokinet. 2018. doi:10.1007/s40262-018-0725-7.
   Web of Science ®Google Scholar
• Liu X, Pichulik T, Wolz -O-O, Dang T-M, Stutz A, Dillen C, Delmiro Garcia M, Kraus H, Dickhöfer S, Daiber E, et al. Human NACHT, LRR, and PYD domain–containing protein 3 (NLRP3) inflammasome activity is regulated by and potentially targetable through Bruton tyrosine kinase. J Allergy Clin Immunol. 2017;140:1054–1067.e10. doi:10.1016/j.jaci.2017.01.017.
   PubMed Web of Science ®Google Scholar
• Horwood NJ, Page TH, McDaid JP, Palmer CD, Campbell J, Mahon T, Brennan FM, Webster D, Foxwell BMJ. Bruton’s tyrosine kinase is required for TLR2 and TLR4-induced TNF, but not IL-6, production. J Immunol. 2006;176:3635–3641. doi:10.4049/jimmunol.176.6.3635.
   PubMed Web of Science ®Google Scholar
• Kakoschky B, Pleli T, Schmithals C, Zeuzem S, Brüne B, Vogl TJ, Korf H-W, Weigert A, Piiper A, Mondelli MU. Selective targeting of tumor associated macrophages in different tumor models. PLoS One. 2018;13:e0193015. doi:10.1371/journal.pone.0193015.
   PubMed Web of Science ®Google Scholar
• Eriksson U, Kurrer MO, Sonderegger I, et al. Activation of dendritic cells through the interleukin 1 receptor 1 is critical for the induction of autoimmune myocarditis. J Exp Med. 2003;197:323–331. doi:10.1084/jem.20021788.
   PubMed Web of Science ®Google Scholar
• Bent R, Moll L, Grabbe S, Bros M. Interleukin-1 beta-A friend or foe in malignancies? Int J Mol Sci. 2018:19. doi:10.3390/ijms19082155.
   PubMed Web of Science ®Google Scholar
• Guo B, Fu S, Zhang J, Liu B, Li Z. Targeting inflammasome/IL-1 pathways for cancer immunotherapy. Sci Rep. 2016;6:36107. doi:10.1038/srep36107.
   PubMed Web of Science ®Google Scholar
• Georgoudaki A-M, Prokopec KE, Boura VF, Hellqvist E, Sohn S, Östling J, Dahan R, Harris R, Rantalainen M, Klevebring D, et al. Reprogramming tumor-associated macrophages by antibody targeting inhibits cancer progression and metastasis. Cell Rep. 2016;15:2000–2011. doi:10.1016/j.celrep.2016.04.084.
   PubMed Web of Science ®Google Scholar
• Luo Y, Zhou H, Krueger J, et al. Targeting tumor-associated macrophages as a novel strategy against breast cancer. J Clin Invest. 2006;116:2132–2141. doi:10.1172/JCI27648.
   PubMed Web of Science ®Google Scholar
• Duan X, He K, Li J, Cheng M, Song H, Liu J, Liu P. Tumor associated macrophages deliver iron to tumor cells via Lcn2. Int J Physiol Pathophysiol Pharmacol. 2018;10:105.
   PubMedGoogle Scholar
• Makela AV, Gaudet JM, Foster PJ. Quantifying tumor associated macrophages in breast cancer: a comparison of iron and fluorine-based MRI cell tracking. Sci Rep. 2017;7:42109. doi:10.1038/srep42109.
   PubMed Web of Science ®Google Scholar
• Moossavi M, Parsamanesh N, Bahrami A, Atkin SL, Sahebkar A. Role of the NLRP3 inflammasome in cancer. Mol Cancer. 2018;17:158. doi:10.1186/s12943-018-0900-3.
   PubMed Web of Science ®Google Scholar
• Kolb R, Liu G-H, Janowski AM, Sutterwala FS, Zhang W. Inflammasomes in cancer: a double-edged sword. Protein Cell. 2014;5:12–20. doi:10.1007/s13238-013-0001-4.
   PubMed Web of Science ®Google Scholar
• Umansky V, Sevko A. Tumor microenvironment and myeloid-derived suppressor cells. Cancer Microenviron. 2013;6:169–177. doi:10.1007/s12307-012-0126-7.
   PubMedGoogle Scholar
• Najjar YG, Rayman P, Jia X, Pavicic PG, Rini BI, Tannenbaum C, Ko J, Haywood S, Cohen P, Hamilton T, et al. Myeloid-derived suppressor cell subset accumulation in renal cell carcinoma parenchyma is associated with intratumoral expression of IL1β, IL8, CXCL5, and Mip-1α. Clin Cancer Res. 2017;23:2346–2355. doi:10.1158/1078-0432.CCR-15-1823.
   PubMed Web of Science ®Google Scholar
• Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883–899. doi:10.1016/j.cell.2010.01.025.
   PubMed Web of Science ®Google Scholar
• Perwez Hussain S, Harris CC. Inflammation and cancer: an ancient link with novel potentials. Int J Cancer. 2007;121:2373–2380. doi:10.1002/ijc.23173.
   PubMed Web of Science ®Google Scholar
• Berraondo P, Minute L, Ajona D, Corrales L, Melero I, Pio R. Innate immune mediators in cancer: between defense and resistance. Immunol Rev. 2016;274:290–306. doi:10.1111/imr.12464.
   PubMed Web of Science ®Google Scholar
• Pal Singh S, Dammeijer F, Hendriks RW. Role of Bruton’s tyrosine kinase in B cells and malignancies. Mol Cancer. 2018;17:57. doi:10.1186/s12943-018-0779-z.
   PubMed Web of Science ®Google Scholar
• Weber ANR, Bittner Z, Liu X, Dang T-M, Radsak MP, Brunner C. Bruton’s tyrosine kinase: an emerging key player in innate immunity. Front Immunol. 2017;8:1454. doi:10.3389/fimmu.2017.01454.
   PubMed Web of Science ®Google Scholar
• Lust JA, Lacy MQ, Zeldenrust SR, Witzig TE, Moon-Tasson LL, Dinarello CA, Donovan KA. Reduction in C-reactive protein indicates successful targeting of the IL-1/IL-6 axis resulting in improved survival in early stage multiple myeloma. Am J Hematol. 2016;91:571–574. doi:10.1002/ajh.24352.
   PubMed Web of Science ®Google Scholar
• Lust JA, Lacy MQ, Zeldenrust SR, Dispenzieri A, Gertz MA, Witzig TE, Kumar S, Hayman SR, Russell SJ, Buadi FK, et al. Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1β-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin Proc. 2009;84:114–122. doi:10.4065/84.2.114.
   PubMed Web of Science ®Google Scholar
• Wu Z, Han X, Qin S, Zheng Q, Wang Z, Xiang D, Zhang J, Lu H, Wu M, Zhu S, et al. Interleukin 1 receptor antagonist reduces lethality and intestinal toxicity of 5-fluorouracil in a mouse mucositis model. Biomed Pharmacother. 2010;64:589–593. doi:10.1016/j.biopha.2010.06.006.
   PubMed Web of Science ®Google Scholar
• Wang X, Gao J, Qian L, Gao J, Zhu S, Wu M, Zhang Y, Guan W, Ye H, Yu Y, et al. Exogenous IL-1Ra attenuates intestinal mucositis induced by oxaliplatin and 5-fluorouracil through suppression of p53-dependent apoptosis. Anticancer Drugs. 2015;26:35–45. doi:10.1097/CAD.0000000000000142.
   PubMed Web of Science ®Google Scholar
• Sauter KAD, Wood LJ, Wong J, Iordanov M, Magun BE. Doxorubicin and daunorubicin induce processing and release of interleukin-1β through activation of the NLRP3 inflammasome. Cancer Biol Ther. 2011;11:1008–1016. doi:10.4161/cbt.11.12.15540.
   PubMed Web of Science ®Google Scholar
• Hickish T, Andre T, Wyrwicz L, et al. MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2017;18:192–201. doi:10.1016/S1470-2045(17)30006-2.
   PubMed Web of Science ®Google Scholar
• De Mooij CEM, Netea MG, Van Der Velden WJFM, Blijlevens NMA. Targeting the interleukin-1 pathway in patients with hematological disorders. Blood. 2017. doi:10.1182/blood-2016-12-754994.
   PubMed Web of Science ®Google Scholar
• Perera AP, Fernando R, Shinde T, Gundamaraju R, Southam B, Sohal SS, Robertson AAB, Schroder K, Kunde D, Eri R. MCC950, a specific small molecule inhibitor of NLRP3 inflammasome attenuates colonic inflammation in spontaneous colitis mice. Sci Rep. 2018;8:8618. doi:10.1038/s41598-018-26775-w.
   PubMed Web of Science ®Google Scholar